Source: Newswire

Press Release: Apexian Pharmaceuticals : APX3330 Phase I Oncology Trial Presented at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Read full article »
Apexian Pharmaceuticals's Competitors | Apexian Pharmaceuticals's News | Apexian Pharmaceuticals's Financials
Stay up-to-date with the latest news on Apexian Pharmaceuticals
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
David Broecker's photo - Interim-CEO of Apexian Pharmaceuticals

Interim-CEO

David Broecker

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Apexian Pharmaceuticals